3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Neoplasm Metastasis
6
Melanoma
5
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Solid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Synovitis, Pigmented Villonodular
1
Solid Tumours
1
Solid Tumour
1
Solid Tumors, KRAS Mutation
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostate Cancer Patients
1
Interventions
Trabectedin
4
Doxorubicin
4
toripalimab
2
brigimadlin
2
belinostat
2
Fulvestrant
2
Dexamethasone
2
tanespimycin
1
soblidotin
1
siremadlin
1
selinexor
1
ridaforolimus
1
ribociclib
1
pembrolizumab
1
olaratumab
1
milademetan
1
enzalutamide
1
cemiplimab
1
atezolizumab
1
TTI-621
1
Sugars
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liposarcoma
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled